Review of resistant hypertension

Current Hypertension Reports

Volumn 8, Issue 5, 2006, Pages 398-402

  Ram, C Venkata C ^a  

^a Texas Blood Pressure Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANOREXIGENIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; COCAINE; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; DECONGESTIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; GLYCYRRHIZA EXTRACT; GUANETHIDINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; INDOMETACIN; LOOP DIURETIC AGENT; MINOXIDIL; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PHENYLPROPANOLAMINE; PROPRANOLOL; RIFAMPICIN; TACROLIMUS; THIAZIDE DIURETIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CLINICAL ASSESSMENT; COMORBIDITY; DISEASE CLASSIFICATION; DRUG ANTAGONISM; HEART STRESS; HUMAN; HYPERTENSION; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PREVALENCE; REVIEW; RISK FACTOR; THERAPY RESISTANCE; TREATMENT FAILURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIAGNOSIS, DIFFERENTIAL; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 33749076697     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0085-9     Document Type: Review

References (25)

1. Thibonnier M: Ambulatory blood pressure monitoring: When is it warranted? Postgrad Med 1992, 91:263-274.
2. Veglio F, Rabbia F, Riva P, et al.: Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin Exp Hypertens 2001, 23:203-211.
3. Verdecchia P: Using out of office blood pressure monitoring in the management of hypertension. Curr Hypertens Rep 2001, 3:400-405.
4. Messerli FH, Ventura HO, Amodeo C: Osler's maneuver and pseudohypertension. N Engl J Med 1985, 312:1548-1551.
5. Mejia AD, Egan BM, Schork NJ, Zweifler AJ: Artefacts in measurement of blood pressure and lack of target organ involvement in the assessment of patients with treatment-resistant hypertension. Ann Intern Med 1990, 112: 270-277.
6. Dustan HP, Tarazi RM, Bravo EL: Dependence of arterial pressure on intravascular volume in treated hypertensive patients. N Engl J Med 1972, 286: 861-866.
7. Fierro-Carrion G, Ram CVS: Nonsteriodal anti-inflammatory drugs (NSAIDs) and blood pressure. Am J Cardiol 1980, 80:775-776.
8. Bloxham CA, Beevers DG, Walker JM: Malignant hypertension and cigarette smoking. Br Med J 1997, 1:581-583.
9. Lavie P, Hoffstein V: Sleep apnea syndrome: a possible contributing factor to resistant hypertension. Sleep 2001, 24:721-725.
10. Tuomilehto J, Enlund H, Salonen JG, Nissinen A: Alcohol, patient compliance and blood pressure control in hypertensive patients. Scand J Soc Med 1984, 12:177-181.
11. van Jaarsveld BC, Krijnen P, Derkx FH, et al.: Resistance to antihypertensive medication as predictor of renal artery stenosis: comparison of two drug regimens. J Hum Hypertens 2001, 15:669-676.
12. Addison C, Varney S, Coats A: The use of ambulatory blood pressure monitoring in managing hypertension according to different treatment guidelines. J Hum Hypertens 2001, 15:535-538.
13. Felmeden DC, Lip GY: Resistant hypertension and the Birmingham Hypertension Square. Curr Hypertens Rep 2001, 3:203-208.
14. Nuesch R, Schroeder K, Dieterle T, et al.: Relation between insufficient response to antihypertensive treatment and poor compliance with treatment: a prospective case-control study. BMJ 2001, 323:142-146.
15. Chobanian AV, Bakris, GL, Black HR, et al.: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, National Heat, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003, 41:1206-1252.
16. Graves J: Management of difficult-to-control hypertension. Mayo Clin Proc 2000, 75:278-284.
17. Setaro J, Black H: Refractory hypertension. N Engl J Med 1992, 327:534-547.
18. Eraker S, Kirscht J, Becker M: Understanding and improving patient compliance. Ann Intern Med 1984 100:258-268.
19. Cuspidi C, Macca G, Sampieri L, et al.: High prevalence of Cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens 2001, 19:2063-2070.
20. Sartori M, Calo LA, Mascagna V, et al.: Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 2006, 19:373-379.
21. Gaddam KK, Pratt-Ubunama MN, Calhoun DA: Aldosterone antagonists: effective add-on therapy for the treatment of resistant hypertension. Expert Rev Cardiovasc Ther 2006, 4:353-359.
22. Calhoun DA: Use of aldosterone antagonists in resistant hypertension. Prog Cardiovasc Dis 2006, 48:387-396.
23. Wolk R, Somers VK: Obesity-related cardiovascular disease: implications of obstructive sleep apnea. Diabetes Obes Metab 2006, 8:250-260.
24. Drager LF, Pereira AC, Barreto-Filho JA, et al.: Phenotypic characteristics associated with hypertension in patients with obstructive sleep apnea. J Hum Hypertens 2006, 20:523-528.
25. Norman D, Loredo JS, Nelesen RA, et al.: Effects of continuous positive airway pressure versus supplemental oxygen on 24 hour ambulatory blood pressure. Hypertension 2006, 47:840-845.